BB Biotech AG's Form 4 filing
Black Diamond Therapeutics, Inc. (BDTX) · filed Apr 20, 2022
- Accession no.
- 0000899243-22-015145
- Filed
- Apr 20, 2022, 12:56 PM ET
- Trade date
- Apr 18-19, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $980.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BB Biotech AGCIK 0000924223 | 10% Owner |
| Biotech Growth N VCIK 0001259869 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 18, 2022 | Common Stock | PPurchaseAcquired | +150,000 | $3.29 | +$493,935 | 4,138,402 | Direct | |
| Apr 19, 2022 | Common Stock | PPurchaseAcquired | +150,000 | $3.24 | +$486,645 | 4,288,402 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.